2020年SYNTAX评分二代：一次物有所值的重塑？ - Suppr | 超能文献

SYNTAX Score II 2020: A Remake Worth the Price of Admission?

作者信息

Squiers John J, DiMaio J Michael

机构信息

Baylor Scott & White The Heart Hospital, Plano, Texas, USA; Baylor University Medical Center, Dallas, Texas, USA.

Baylor Scott & White The Heart Hospital, Plano, Texas, USA.

出版信息

J Am Coll Cardiol. 2021 Sep 21;78(12):1239-1241. doi: 10.1016/j.jacc.2021.07.028.

DOI:10.1016/j.jacc.2021.07.028

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

SYNTAX Score II 2020: A Remake Worth the Price of Admission?

J Am Coll Cardiol. 2021 Sep 21;78(12):1239-1241. doi: 10.1016/j.jacc.2021.07.028.

2

Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II.

Lancet. 2013 Feb 23;381(9867):639-50. doi: 10.1016/S0140-6736(13)60108-7.

3

Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation.

Lancet. 2020 Oct 31;396(10260):1399-1412. doi: 10.1016/S0140-6736(20)32114-0. Epub 2020 Oct 8.

4

Risk stratification in 3-vessel coronary artery disease: Applying the SYNTAX Score II in the Heart Team Discussion of the SYNTAX II trial.

Catheter Cardiovasc Interv. 2015 Nov 15;86(6):E229-38. doi: 10.1002/ccd.25907. Epub 2015 May 6.

5

Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II.

Eur Heart J. 2015 May 21;36(20):1231-41. doi: 10.1093/eurheartj/ehu518. Epub 2015 Jan 12.

6

Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial.

Eur Heart J. 2014 Oct 21;35(40):2821-30. doi: 10.1093/eurheartj/ehu213. Epub 2014 May 21.

7

Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.

Lancet. 2013 Feb 23;381(9867):629-38. doi: 10.1016/S0140-6736(13)60141-5.

8

Individual Long-Term Mortality Prediction Following Either Coronary Stenting or Bypass Surgery in Patients With Multivessel and/or Unprotected Left Main Disease: An External Validation of the SYNTAX Score II Model in the 1,480 Patients of the BEST and PRECOMBAT Randomized Controlled Trials.

JACC Cardiovasc Interv. 2016 Aug 8;9(15):1564-72. doi: 10.1016/j.jcin.2016.04.023.

9

Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.

Lancet. 2019 Oct 12;394(10206):1325-1334. doi: 10.1016/S0140-6736(19)31997-X. Epub 2019 Sep 2.

10

Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial.

Catheter Cardiovasc Interv. 2020 Nov;96(5):E516-E526. doi: 10.1002/ccd.28898. Epub 2020 Apr 15.

引用本文的文献

1

Assessment of TVT and STS Risk Score Performances in Patients Undergoing Transcatheter Aortic Valve Replacement.

J Soc Cardiovasc Angiogr Interv. 2023 Apr 21;2(3):100600. doi: 10.1016/j.jscai.2023.100600. eCollection 2023 May-Jun.